Panos Kanavos
Panos Kanavos
Associate Professor in International Health Policy
Patvirtintas el. paštas - Pagrindinis puslapis
The rising burden of cancer in the developing world
P Kanavos
Annals of oncology 17, viii15-viii23, 2006
Assessing the economic challenges posed by orphan drugs
MF Drummond, DA Wilson, P Kanavos, P Ubel, J Rovira
International journal of technology assessment in health care 23 (1), 36-42, 2007
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
A Angelis, A Lange, P Kanavos
The European Journal of Health Economics 19, 123-152, 2018
Socio-economic burden of rare diseases: a systematic review of cost of illness evidence
A Angelis, D Tordrup, P Kanavos
Health Policy 119 (7), 964-979, 2015
Encouraging the use of generic medicines: implications for transition economies
DR King, P Kanavos
Croatian medical journal 43 (4), 462-469, 2002
Ensuring value for money in health care: the role of health technology assessment in the European Union
C Sorenson, M Drummond, P Kanavos
WHO Regional Office Europe, 2008
Early chronic kidney disease: diagnosis, management and models of care
OJ Wouters, DJ O'donoghue, J Ritchie, PG Kanavos, AS Narva
Nature Reviews Nephrology 11 (8), 491-502, 2015
Diabetes expenditure, burden of disease and management in 5 EU countries
P Kanavos, S van den Aardweg, W Schurer
LSE health, London school of Economics 113, 2012
Multiple criteria decision analysis (MCDA) for evaluating new medicines in health technology assessment and beyond: the advance value framework
A Angelis, P Kanavos
Social Science & Medicine 188, 137-156, 2017
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
A Ferrario, P Kanavos
Social science & medicine 124, 39-47, 2015
Competition in off-patent drug markets: Issues, regulation and evidence
P Kanavos, J Costa-Font, E Seeley
Economic policy 23 (55), 500-544, 2008
Managed entry agreements for pharmaceuticals: the European experience
A Ferrario, P Kanavos
EMINet, 2013
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review
AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ...
Globalization and health 9, 1-12, 2013
Comparing generic drug markets in Europe and the United States: prices, volumes, and spending
OJ Wouters, PG Kanavos, M McKee
The Milbank Quarterly 95 (3), 554-601, 2017
The implementation of managed entry agreements in Central and Eastern Europe: findings and implications
A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ...
Pharmacoeconomics 35, 1271-1285, 2017
Reference pricing for drugs: is it compatible with US health care?
P Kanavos, U Reinhardt
Health Affairs 22 (3), 16-30, 2003
Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom
SG Morgan, M McMahon, C Mitton, E Roughead, R Kirk, P Kanavos, ...
Health Affairs 25 (2), 337-347, 2006
Pharmaceutical parallel trade in Europe: stakeholder and competition effects
P Kanavos, J Costa-Font
Economic policy 20 (44), 758-798, 2005
Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy
TL Jackson, E Nicod, A Angelis, F Grimaccia, AT Prevost, ARH Simpson, ...
Retina 33 (10), 2012-2017, 2013
Medical technology procurement in Europe: a cross-country comparison of current practice and policy
C Sorenson, P Kanavos
Health policy 100 (1), 43-50, 2011
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20